WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for MDGL

Based on 3 analysts offering 12 month price targets for Madrigal Pharmaceuticals Inc.
Min Forecast
$75.00+2.57%
Avg Forecast
$138.33+89.19%
Max Forecast
$170.00+132.49%

Should I buy or sell MDGL stock?

Based on 3 analysts offering ratings for Madrigal Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MDGL stock forecasts and price targets.

MDGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
B. Riley Securities
Top 2%
99
HoldDowngrades$75.00+2.57%2022-07-08
JMP Securities
Bottom 11%
11
BuyMaintains$170.00+132.49%2022-05-10
Oppenheimer
Top 9%
92
BuyMaintains$170.00+132.49%2022-05-10

1 of 1

Forecast return on equity

Is MDGL forecast to generate an efficient return?
Company
907.27%
Industry
14.69%
Market
64.75%
MDGL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MDGL forecast to generate an efficient return on assets?
Company
61.02%
Industry
13.16%
MDGL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MDGL earnings per share forecast

What is MDGL's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
-$15.19
Avg 2 year Forecast
-$12.28
Avg 3 year Forecast
-$4.99

MDGL revenue forecast

What is MDGL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$62.0M
Avg 2 year Forecast
$84.1M
Avg 3 year Forecast
$236.6M

MDGL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MDGL$73.12$138.33+89.19%Buy
TVTX$19.54$38.80+98.57%Strong Buy
ADPT$8.65$15.38+77.75%Hold
BLU$9.81$20.50+108.97%Strong Buy
QURE$26.29$49.25+87.33%Strong Buy

Madrigal Pharmaceuticals Stock Forecast FAQ

Is Madrigal Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MDGL) stock is to Buy MDGL stock.

Out of 3 analysts, 0 (0%) are recommending MDGL as a Strong Buy, 2 (66.67%) are recommending MDGL as a Buy, 1 (33.33%) are recommending MDGL as a Hold, 0 (0%) are recommending MDGL as a Sell, and 0 (0%) are recommending MDGL as a Strong Sell.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is MDGL's earnings growth forecast for 2022-2024?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.96%.

Madrigal Pharmaceuticals's earnings in 2022 is -$273,994,000.On average, 8 Wall Street analysts forecast MDGL's earnings for 2022 to be -$259,800,570, with the lowest MDGL earnings forecast at -$283,232,221, and the highest MDGL earnings forecast at -$232,948,240. On average, 8 Wall Street analysts forecast MDGL's earnings for 2023 to be -$210,029,691, with the lowest MDGL earnings forecast at -$299,993,548, and the highest MDGL earnings forecast at -$152,220,216.

In 2024, MDGL is forecast to generate -$85,345,941 in earnings, with the lowest earnings forecast at -$336,423,780 and the highest earnings forecast at $105,698,981.

What is MDGL's revenue growth forecast for 2022-2024?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.76%.

Madrigal Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast MDGL's revenue for 2022 to be $1,060,410,490, with the lowest MDGL revenue forecast at $1,060,410,490, and the highest MDGL revenue forecast at $1,060,410,490. On average, 4 Wall Street analysts forecast MDGL's revenue for 2023 to be $1,438,310,003, with the lowest MDGL revenue forecast at $815,831,942, and the highest MDGL revenue forecast at $1,812,959,870.

In 2024, MDGL is forecast to generate $4,046,782,981 in revenue, with the lowest revenue forecast at $913,150,259 and the highest revenue forecast at $10,415,967,555.

What is MDGL's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: MDGL) forecast ROA is 61.02%, which is higher than the forecast US Biotechnology industry average of 13.16%.

What is MDGL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MDGL price target, the average MDGL price target is $138.33, with the highest MDGL stock price forecast at $170.00 and the lowest MDGL stock price forecast at $75.00.

On average, Wall Street analysts predict that Madrigal Pharmaceuticals's share price could reach $138.33 by Jul 8, 2023. The average Madrigal Pharmaceuticals stock price prediction forecasts a potential upside of 89.19% from the current MDGL share price of $73.12.

What is MDGL's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's current Earnings Per Share (EPS) is -$16.04. On average, analysts forecast that MDGL's EPS will be -$15.19 for 2022, with the lowest EPS forecast at -$16.56, and the highest EPS forecast at -$13.62. On average, analysts forecast that MDGL's EPS will be -$12.28 for 2023, with the lowest EPS forecast at -$17.54, and the highest EPS forecast at -$8.90. In 2024, MDGL's EPS is forecast to hit -$4.99 (min: -$19.67, max: $6.18).

What is MDGL's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: MDGL) forecast ROE is 907.27%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.